DUBAI, United Arab Emirates — A breakthrough in medical artificial intelligence from an African-led health technology firm is set to transform breast cancer care by predicting chemotherapy resistance in as little as 21 days. The platform, developed by Chil AI Lab, addresses a critical diagnostic gap where patients typically wait up to six months to determine if their treatment is effective.
The technology distinguishes itself from conventional “black box” algorithms by quantifying its own certainty. Rather than delivering a binary result, the system provides a confidence score for every scan. This approach allows the AI to function as a digital specialist that identifies its own limitations, automatically flagging uncertain cases for immediate review by an oncologist.
Dr. Shamim Nabuuma Kaliisa, who leads the project, said the ability of a tool to acknowledge when it is unsure is a vital safety feature. She noted that by providing a system that can quantify its own certainty, the lab is giving doctors a tool they can trust to move away from guesswork and pivot treatment the moment data indicates a high probability of failure.
The platform was validated through a 24-month study involving 306 patients across multiple cancer centers in Africa. Clinical results confirmed that early confidence scores accurately predicted long-term treatment outcomes.
The Chil AI Lab team is scheduled to present their findings at the upcoming World Health Assembly. The presentation will highlight how advanced, life-saving technology developed in Africa can address urgent needs in emerging healthcare markets.
Following the success of the breast cancer trials, the firm is expanding the platform to include additional cancer types and further refine its predictive accuracy.
